Disclaimer: Stem cell and exosome programs coordinated through Astramedica's partner clinics are not FDA-approved for therapeutic use in the United States. These programs are administered by independent, licensed physicians at partner facilities. Individual results may vary. This content is for educational purposes only and does not constitute medical advice. — With that context established, this article provides an educational overview of what stem cell and exosome support programs involve, how they are typically structured at partner clinics in Turkey, and what patients should understand before considering them.
What are stem cells and exosomes?
Stem cells are undifferentiated biological cells capable of developing into specialized cell types. They are the subject of extensive scientific research worldwide. Exosomes are nano-sized vesicles involved in intercellular communication, carrying proteins, lipids, and genetic material between cells. Both are areas of active scientific investigation with evolving understanding.
It is important to distinguish between the scientific research context and the clinical application context. Research into these biological materials is ongoing. Clinical programs that use them are offered under physician supervision at facilities in various jurisdictions. These programs are not approved by the FDA or any US federal regulatory body.
How these programs are typically structured abroad
At partner clinics in Turkey, stem cell and exosome support programs are typically administered under the supervision of independent, licensed physicians. The process generally includes an initial clinical assessment, laboratory preparation of biological materials, physician-supervised administration, and a post-procedure monitoring period.
The specific protocol — including the type of biological material, the volume used, and the method of administration — is determined by the independent physician based on the patient's case. Astramedica does not design, modify, or influence clinical protocols.
Regulatory context for US patients
Stem cell and exosome programs coordinated through Astramedica's partner clinics are not FDA-approved for therapeutic use in the United States. The FDA considers stem cell programs experimental at this point. Patients considering these programs should understand that the regulatory context in Turkey may differ from the United States, and that traveling abroad for such programs does not change their regulatory status under US law.
Astramedica communicates this regulatory context transparently to every patient during the coordination process. Patients who are not comfortable with the experimental status of these programs are encouraged to consult with their domestic healthcare providers before making a decision.
What patients should evaluate before proceeding
Patients are best served by evaluating these programs based on verifiable criteria rather than marketing language. Key considerations include the credentials and experience of the supervising physician, the accreditation status of the facility, the transparency of the clinical explanation provided, and the realism of the expectations set during the consultation.
- What specific credentials does the supervising physician hold?
- How does the clinic explain what the program can and cannot achieve?
- Are limitations and variable outcomes discussed openly?
- Is the facility accredited by a recognized international body?
- Does the program description avoid absolute claims or exaggerated expectations?
Astramedica's role in the process
Astramedica coordinates access to these programs. It does not manufacture biological materials, design clinical protocols, or administer procedures. The coordination role includes patient intake, partner clinic matching, communication support, travel logistics, and post-journey follow-up.
Disclaimer: Stem cell and exosome programs coordinated through Astramedica's partner clinics are not FDA-approved for therapeutic use in the United States. These programs are administered by independent, licensed physicians at partner facilities. Individual results may vary. This content is for educational purposes only and does not constitute medical advice.
Frequently Asked Questions
Are stem cell programs legal?+
Some jurisdictions may operate under different legal and regulatory frameworks, but these programs are not FDA-approved for therapeutic use in the US. Patients should consult legal and medical advisors as appropriate.
Does Astramedica provide these programs directly?+
No. Astramedica is a coordination company. All programs are administered by independent, licensed physicians at partner clinics in Turkey.
Can I expect specific outcomes?+
Individual results may vary. No specific outcomes should be expected or implied. Patients should discuss realistic expectations directly with the independent physician during the clinical consultation.
How do I know if I am a candidate?+
Candidacy is determined by the independent physician at the partner clinic, not by Astramedica. The clinical review process assesses eligibility based on the patient's medical history and the physician's professional judgment.
What is the regulatory status of exosome products?+
Exosome-based products are not FDA-approved for any therapeutic use. The FDA has issued public communications regarding the regulatory status of these products, and patients are encouraged to review this information as part of their decision-making process.
